Drugs / QY201
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05525715 | Oct 2022 → Dec 2025 | atopic eczema | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07712523 | Nov 2025 → Dec 2026 expected | — | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07712536 | Jun → Dec 2025 | atopic eczema | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07180511 | Mar 2025 → May 2027 expected | atopic eczema | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. | Enrolling by invitation | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QY201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07712523 ↗ |